Form 4 for IDXX Idexx Laboratories
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-10 · accession 0001567619-22-020130 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-11-14 | 2022-11-10+ | IDXX | Turner Kathy V | SVP | S - Sale+OE | $426.70 | -13.9K | 6,923 | -67% | -$5.92M |
| DM | 2022-11-14 | 2022-11-10+ | IDXX | Turner Kathy V | SVP | M - OptEx | $189.23 | +13.9K | 12.2K | New | +$2.63M |
| DM | 2022-11-14 | 2022-11-10+ | IDXX | Turner Kathy V | SVP | M - OptEx | — | -13.9K | 3,056 | -82% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-10 | S | D | 2,655 | $410.02 | 9,578.39 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $410.00 to a high of $410.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2022-11-10 | S | D | 25 | $406.11 | 9,553.39 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $406.10 to a high of $406.115 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 3 | Common | Common Stock | 2022-11-11 | S | D | 3,000 | $436.06 | 6,923.39 | D | — | — | (F6) Represents the weighted average price of the shares sold ranging from a low of $435.00 to a high of $435.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2022-11-11 | M | A | 8,567 | $178.26 | 15,490.39 | D | — | — | |
| 5 | Common | Common Stock | 2022-11-11 | S | D | 2,567 | $442.05 | 12,293.39 | D | — | — | (F5) Represents the weighted average price of the shares sold ranging from a low of $442.00 to a high of $442.0125 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 6 | Common | Common Stock | 2022-11-11 | S | D | 3,000 | $438.00 | 9,923.39 | D | — | — | |
| 7 | Common | Common Stock | 2022-11-10 | M | A | 5,310 | $206.94 | 12,233.39 | D | — | — | (F1) Includes a total of 37 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022, June 30, 2022 and, September 30, 2022. |
| 8 | Common | Common Stock | 2022-11-10 | S | D | 2,630 | $405.21 | 6,923.39 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $405.00 to a high of $405.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 9 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2022-11-11 | M | D | 8,567 | — | 1,581 | D | $178.26 · — to 2028-02-13 | 8,567 Common Stock | (F10) Not applicable. (F9) Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2019. |
| 10 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2022-11-10 | M | D | 5,310 | — | 3,056 | D | $206.94 · — to 2029-02-13 | 5,310 Common Stock | (F10) Not applicable. (F8) Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |